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Pre-eclampsia: a maternal manifestation of a fetal adaptive response?
More than 70 years ago, Ernest W. Page published what
is perhaps one of the most insightful articles regarding
the pathophysiology of pre-eclampsia1. In this article,
using a combination of induction and deduction, Dr
Page advanced key concepts consistent with the notions
of ‘failure of physiologic transformation of the spiral
arteries’, ‘the fetal–maternal conflict’ and the need for a
‘placental pressor substance’ as part of the mechanisms
of disease of pre-eclampsia. Since the publication of this
seminal paper, there has been an accumulation of evidence
to support the validity of these postulates.
Using teleologic reasoning, Dr Page wrote that, ‘if
the placenta should be unable to obtain a sufficient
maternal circulation for its demands, it might be capable
of increasing this supply by raising the systemic blood
pressure. Since there are no nervous connections by
which the placenta could accomplish this, such a postulate
necessitates the concept of a placental pressor substance.’
This revolutionary concept, described so eloquently in
1939, has proven to be correct, as demonstrated by a
growing body of evidence indicating that anti-angiogenic
factors of placental origin (including the soluble form
of vascular endothelial growth factor (VEGF) receptor 1
(sFlt-1), soluble endoglin (s-Eng)2,3 and others) play a
central role in the pathophysiology of pre-eclampsia.
Indeed, clinical and experimental evidence indicates that
an imbalance between angiogenic factors (such as VEGFs
and placental growth factor (PlGF)) and anti-angiogenic
factors are associated with the maternal manifestations of
pre-eclampsia, eclampsia and HELLP syndrome4.
Changes in the maternal plasma/serum concentrations
of angiogenic-related factors occur before presentation of
pre-eclampsia: elevated maternal serum/plasma concen-
trations of anti-angiogenic factors have been described
in the first and second trimesters in patients who then
developed pre-eclampsia in the index pregnancy2,5–23.
Moreover, the measurement of angiogenic factors in com-
bination with uterine artery Doppler velocimetry and
other parameters has been reported to play an important
role in the identification of patients at risk of developing
pre-eclampsia18,24,25. For example, the combination of a
low maternal plasma concentration of PlGF and abnormal
uterine artery Doppler velocimetry in the second trimester
confers a very high risk for the development of early-
onset pre-eclampsia (< 34 weeks) (odds ratio (OR), 43.8
(95% CI, 18.48–103.89))24. In this issue of the Journal,
Wortelboer et al.26 report a negative correlation between
the maternal serum concentration of PlGF, among other
biochemical markers, and impedance of blood flow in the
uterine arteries during the first trimester of pregnancy.
This is consistent with a report indicating that a combina-
tion of low maternal serum concentrations of PlGF, high
uterine artery pulsatility index and other parameters in the
first trimester identified 93.1% of patients who developed
pre-eclampsia requiring delivery before 34 weeks18.
Uteroplacental ischemia may result in maternal hyper-
tension and increased circulating concentrations of anti-
angiogenic factors (sFlt-1 and s-Eng, among others).
Evidence supporting this view includes4: 1) reduced uter-
ine perfusion in pregnant non-human primates and rats
is associated with hypertension and increased placental
expression of anti-angiogenic factors; 2) cytotrophoblast
cultured under hypoxic conditions upregulates mRNA
expression and production of sFlt-1 in the supernatant;
3) increased expression of human placental sFlt-1 is medi-
ated by hypoxia inducible factor-1 (HIF-1); 4) among
patients with pre-eclampsia, the higher the impedance to
blood flow in the uterine arteries (a surrogate maker of
chronic uteroplacental ischemia), the higher the mater-
nal plasma concentration of anti-angiogenic factors; and
5) histological lesions suggestive of chronic trophoblast
ischemia have been associated with hypertension, pro-
teinuria and angiogenic imbalances. These lesions include
decidual arteriolopathy, central villi infarction and hyper-
maturity of villi in ‘classic pre-eclampsia’, severe villous
edema in ‘mirror syndrome’ and ‘avascular’ villi in mole
and partial mole.
Dr Page wrote that the placenta ‘appears to be a
ruthless parasitic organ existing solely for the mainte-
nance and protection of the fetus, perhaps too often to
the disregard of the maternal organism’. According to
the conceptual framework of the ‘fetomaternal conflict’,
fetal growth and development can sometimes happen
at the expense of maternal wellbeing. Using this frame-
work, it is difficult to believe that reproductive evolution
allowed chronic trophoblast ischemia to lead to angio-
genic imbalances which may endanger the survival of
both the mother and the fetus. We speculate that, in pre-
eclamptic patients, chronic uteroplacental ischemia limits
the amount of substrates available for fetal growth. In
turn, the fetus may signal the placental release of anti-
angiogenic factors in order to increase the maternal blood
pressure in an attempt to compensate for the limited
blood flow to placental and fetal tissues. The magnitude
of angiogenic imbalances, gene–environment interaction
and other factors may determine whether a patient with
chronic trophoblast ischemia presents with pre-eclampsia,
fetal growth restriction or both, or any of the other
intermediate phenotypes. Chronic trophoblast ischemia
appears to be less relevant in the pathophysiology of
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late-onset pre-eclampsia (> 34 weeks). Indeed, the latter
is frequently associated with fetuses that are adequate
or large-for-gestational age. Thus, we propose that, in
late-onset pre-eclampsia, an increased fetal demand for
substrates that surpasses the placental ability to sustain
fetal growth may induce fetal signaling for placental over-
production of anti-angiogenic factors and subsequent
‘compensatory’ maternal hypertension4. This is in keeping
with Dr Page’s proposal that a ‘relative ischemia of gravid
uterus may, of course, result from an increased demand
for blood supply, an actual decrease of maternal blood
supply, or a failure of the developing uterine circulation to
keep pace with the increasing demand.’ The latter of these
three is consistent with observations that high impedance
to blood flow in both uterine arteries is associated with
failure of physiologic transformation of the spiral arteries
in placental bed biopsies from patients delivering small-
for-gestational age (SGA) neonates27–30 and those with
pre-eclampsia27–29,31. Thus, it is possible that abnormal
trophoblast invasion of the spiral arteries32,33 may lead to
chronic trophoblast ischemia, which in turn may induce
angiogenic imbalances during pregnancy. The magnitude
of the imbalances, genetic predisposition34 or other factors
may determine whether a patient with chronic trophoblast
ischemia delivers an SGA neonate, develops pre-eclampsia
or both, or develops one of the intermediate phenotypes
(such as gestational hypertension, gestational proteinuria
or pre-eclampsia associated with mirror syndrome and
molar pregnancy)4.
In his original paper, Dr Page put emphasis on the role
of the placenta in the pathophysiology of pre-eclampsia.
However, there is growing evidence that the fetus may
play a central role in the mechanisms of disease in pre-
eclampsia; after all, the placenta is considered to be of
fetal origin. A striking example of the role of the fetus
is the remission of pre-eclampsia following the death
of the growth-restricted fetus in discordant twins35–37
or following correction of fetal hydrops in parvovirus
infection38. Moreover, increased impedance to blood flow
in the umbilical artery (a surrogate marker of impaired
fetal perfusion of the placenta) is associated with ele-
vated maternal plasma concentration of anti-angiogenic
factors (sFlt-1)39 and reduced maternal plasma concen-
trations of angiogenic factors (PlGF)40. Recent studies
suggest that, in the context of chronic uteroplacental
ischemia, the fetus may use the adenosine system and/or
other signaling mechanisms to increase the maternal blood
pressure in an attempt to increase uteroplacental blood
flow. An elegant in-vitro study provides compelling evi-
dence in support of this view41: the authors determined the
adenosine concentrations in fetal venous perfusates using
isolated dual-perfused human placental cotyledons, with
the fetal compartment and the intervillous space being
perfused under controlled conditions. They reported that
cessation of ‘maternal’ perfusion was associated with a
two- to six-fold increase in fetal venous perfusate con-
centrations of adenosine and a concomitant increase in
fetoplacental perfusion pressure. Furthermore, perfusate
pressure and the concentration of adenosine in the fetal
compartment returned to baseline levels on reperfusion
of the ‘maternal’ circuit. A more recent study42 using pla-
cental explants from rats found that exogenous adenosine
administration significantly increased the concentration
of sFlt-1 in normoxic conditions, and that the addition of
dipyridamole (an adenosine transporter antagonist which
increases extracellular adenosine concentration) to cell
cultures led to a 1.6-fold increase in the concentration
of sFlt-1. Moreover, although hypoxia was associated
with a two-fold increase in the concentrations of sFlt-1 in
the supernatant, blockade of adenosine signaling (using
a non-specific adenosine receptor antagonist) blunted the
hypoxic effect on the concentrations of sFlt-1 and VEGF to
a level similar to that in normoxic conditions. These results
indicate that adenosine signaling is important for placental
overexpression and release of sFlt-1 under both normoxic
and hypoxic conditions. This is consistent with another
recent study comparing the fetal plasma concentrations of
adenosine from normal pregnancies with those from pre-
eclamptic ones, which found that adenosine levels were
significantly higher in patients with pre-eclampsia than in
those with normal pregnancies43. Moreover, this study
sub-classified pre-eclamptic patients into those with and
those without abnormal uterine artery Doppler velocime-
try (UADV) and found that fetal plasma concentrations
of adenosine in patients with pre-eclampsia and abnor-
mal UADV, but not in those with pre-eclampsia and
normal UADV, were significantly higher than in normal
pregnancies. The authors concluded that patients with
pre-eclampsia and with sonographic evidence of chronic
uteroplacental ischemia have high fetal plasma concen-
trations of adenosine, and proposed that in patients with
chronic uteroplacental ischemia the fetus may use the
adenosine system and/or other signaling mechanisms to
increase the maternal blood pressure in an attempt to
increase uteroplacental blood flow.
Visionaries such as Dr Page advanced our under-
standing of complex pregnancy complications such as
pre-eclampsia and the role of the placenta in its mech-
anisms of disease. However, the role of the fetus in
the maternal manifestations of pregnancy complications
deserves more attention. Recent evidence suggests that the
fetus may play a central role in the clinical manifestations
of pre-eclampsia which might have fetal survival value in
the context of uteroplacental ischemia. It is possible that
the combination of ultrasound and biochemical markers
in the first and second trimesters of pregnancy may con-
tribute to the identification of patients at high risk for
early-onset and/or severe pre-eclampsia, who may benefit
from interventions such as the one described by Tra-
pani Jr et al. in this issue of the Journal44. These authors
reported that transdermal administration of nitroglycerin
in patients with severe pre-eclampsia is associated with a
significant reduction in the impedance to blood flow in the
uterine and umbilical arteries as well as a significant reduc-
tion in the maternal mean arterial blood pressure. Future
randomized controlled trials would determine whether
this or other similar interventions could improve maternal
and neonatal outcomes.
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